Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294597 | 0.78 | RXFP1 (0.47) | ALDH1A1TP53SMN1; SMN2AHRLMNA | |
| SCHEMBL29713811 | 0.78 | RXFP1 (0.47) | ALDH1A1TP53SMN1; SMN2AHRLMNA | |
| SCHEMBL29531208 | 0.78 | RHEB (0.58) | RHEBALDH1A1AHRCMA1F7 | |
| SCHEMBL1022450 | 0.78 | RHEB (0.58) | RHEBALDH1A1AHRCMA1F7 | |
| SCHEMBL31735582 | 0.77 | RHEB (0.47) | RHEBALDH1A1AHRCMA1AURKA | |
| SCHEMBL24037999 | 0.75 | ALDH1A1 (0.37) | RHEBALDH1A1TP53SMN1; SMN2AHR | |
| SCHEMBL5704871 | 0.75 | RHEB (0.54) | RHEBALDH1A1SMN1; SMN2AHRCMA1 | |
| SCHEMBL1019021 | 0.75 | AHR (0.45) | ALDH1A1AHRAURKAHPGDALOX15 | |
| SCHEMBL12113048 | 0.75 | ALDH1A1 (0.37) | RHEBALDH1A1TP53SMN1; SMN2AHR | |
| SCHEMBL1019925 | 0.75 | AHR (0.45) | RHEBALDH1A1AHRNR4A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116594-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海安诺达生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-5187283-A | Reacting indole(or derivatives) with organic hydroperoxide in presence of group 4,5 or 6 metals and removing water during reaction | MITSUI TOATSU CHEMICALS, INC. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0487322-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5112987-A | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, INC. (JP) | 1992-05-12 | — | — | US | disclosed |
| US-4992556-A | Reacting indole compound with organic hydroperoxide | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-02-12 | — | — | US | disclosed |
| US-4973706-A | OXIDATION OF INDOLE WITH HYDROPEROXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-11-27 | — | — | US | disclosed |
| US-4966977-A | PEROXIDATION OF INDOLE COMPOUND | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0368508-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0339887-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0335524-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-10-04 | — | — | EP | disclosed |
| EP-0330419-A2 | Process for the preparation of indigo compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | RHEB 2204/4885ALDH1A1 4362/4885TP53 489/4885 |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | RHEB 1446/4885ALDH1A1 4311/4885TP53 939/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | RHEB 2204/4885ALDH1A1 4362/4885TP53 489/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | RHEB 1446/4885ALDH1A1 4311/4885TP53 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.